<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398670</url>
  </required_header>
  <id_info>
    <org_study_id>P3-LIS-IMSFDA-01</org_study_id>
    <nct_id>NCT01398670</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics</brief_title>
  <official_title>Comparison of the Immunogenicity of Wockhardt's Insulin Analogue Lispro and Lispro Mix With Eli Lilly's Insulin Analogue Humalog® and Humalog® Mix in Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel group comparison of the immunogenicity safety of Wockhardt's&#xD;
      Insulin analogue Lispro and lispro Mix with Eli Lilly's Insulin analogue Humalog® and&#xD;
      Humalog® Mix in patients with Type 1 Diabetes Mellitus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate and compare the Immunogenicity safety of Wockhardt's Insulin analogue Lispro and&#xD;
      lispro Mix with Eli Lilly's Insulin analogue Humalog® and Humalog® Mix in Type I Diabetic&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not initiated&#xD;
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the immunogenic response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the immunogenicity with hypoglycemia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>Lispro arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lispro and Lispro Mix 75/25 /Lispro Mix 50/50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50&#xD;
The drugs would be administered subcutaneously</description>
    <arm_group_label>Lispro arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50&#xD;
The drugs would be administered subcutaneously</description>
    <arm_group_label>Humalog® arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who understand the nature of the study and are willing to provide written&#xD;
             informed consent.&#xD;
&#xD;
          2. Patients who have been pre-diagnosed as cases of type-1 diabetes for a period not less&#xD;
             than 1 year&#xD;
&#xD;
          3. Male or Female Patients ≥ 18 and &lt; 55 years of age.&#xD;
&#xD;
          4. Patients with body mass index (BMI) of 18.0 to 30.0 kg/m2&#xD;
&#xD;
          5. Patients who are cooperative, reliable, and agree to have regular injections of&#xD;
             insulin and are willing to comply with protocol procedures.&#xD;
&#xD;
          6. Ability to use the self glucose-monitoring device and to self inject insulin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or lactating, or not practicing adequate contraception.&#xD;
&#xD;
          2. A Patient with compromised hepatic or renal function&#xD;
&#xD;
          3. A Patient who is an employee of the Investigator, or a patient who has a direct&#xD;
             involvement with the trial or other trials under the direction of the Investigator.&#xD;
&#xD;
          4. A Patient who has been treated with other investigational agent or devices within the&#xD;
             previous 30 days, has planned use of investigational drugs or devices, or has been&#xD;
             previously randomized in this trial.&#xD;
&#xD;
          5. A Patient with history or evidence of allergy to insulin preparations.&#xD;
&#xD;
          6. A Patients who is currently receiving or has received, within the last year, any&#xD;
             immunomodulator medications.&#xD;
&#xD;
          7. Patients unlikely to comply with the study protocol e.g. unable to return periodically&#xD;
             for subsequent visits.&#xD;
&#xD;
          8. Patients who are judged by the investigator as inappropriate to participate in the&#xD;
             study for any reason other than those mentioned.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Rasendrakumar Jha</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Diabetes</keyword>
  <keyword>Wockhardt's Insulin analogue Lispro</keyword>
  <keyword>Humalog®</keyword>
  <keyword>Humalog Mix</keyword>
  <keyword>Wockhardt</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

